Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Consensus Target Price from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $43.00.

Several brokerages have issued reports on BCAX. Morgan Stanley began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective on the stock. HC Wainwright initiated coverage on Bicara Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $42.00 price objective on the stock. TD Cowen initiated coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating on the stock. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target on the stock. Finally, Rodman & Renshaw initiated coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target on the stock.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $11.60 on Monday. The company has a fifty day simple moving average of $17.08. Bicara Therapeutics has a 12 month low of $11.51 and a 12 month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in BCAX. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the fourth quarter valued at about $31,000. SG Americas Securities LLC acquired a new stake in Bicara Therapeutics in the fourth quarter valued at about $147,000. Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics in the third quarter valued at about $229,000. Barclays PLC acquired a new stake in Bicara Therapeutics in the third quarter valued at about $255,000. Finally, Jane Street Group LLC acquired a new stake in Bicara Therapeutics in the third quarter valued at about $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.